Santen Pharmaceutical CoSNPHY -2.57%82 FCF Yield % is 4.27 as of Jun. 28, 2026, which is 17% above its 10-year median of 3.65. GuruFocus rates SNPHY with a GF Score™ of 82/100 and a GF Value™ of $10.08 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 1,001 Drug Manufacturers companies, Santen Pharmaceutical Co ranks better than 70.23% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Santen Pharmaceutical Co FCF Yield % Related Terms
Santen Pharmaceutical Co FCF Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Santen Pharmaceutical Co's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Santen Pharmaceutical Co FCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Santen Pharmaceutical Co's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Santen Pharmaceutical Co's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Santen Pharmaceutical Co (SNPHY) has a FCF Yield % of 4.27 as of Jun. 28, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Santen Pharmaceutical Co and its competitors. This is 17% above median its historical median of 3.65. According to the industry distribution chart, Santen Pharmaceutical Co ranks #298 out of 1001 companies in the Drug Manufacturers industry, placing it in the top 29.8%.
Is Santen Pharmaceutical Co's FCF Yield % too high?
Santen Pharmaceutical Co's current FCF Yield % of 4.27 is 17% above median its 10-year median of 3.65. The Drug Manufacturers industry median FCF Yield % is 0.64. Santen Pharmaceutical Co's value of 4.27 is 567.2% above this industry median. Based on the distribution chart, Santen Pharmaceutical Co ranks #298 out of 1001 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Santen Pharmaceutical Co has a GF Score™ of 82/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Santen Pharmaceutical Co's FCF Yield % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Santen Pharmaceutical Co ranks #298 out of 1001 companies for FCF Yield %. This puts Santen Pharmaceutical Co in the upper half of its industry. The industry median FCF Yield % is 0.64. Santen Pharmaceutical Co's value of 4.27 is 567.2% above this benchmark. While the company's 10-year median is 3.65 vs. the industry median of 0.64, Santen Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Drug Manufacturers company?
The median FCF Yield % among Drug Manufacturers companies is 0.64, based on 1,001 companies in the industry. Companies in the top quartile (top 25%) have a FCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Santen Pharmaceutical Co's current FCF Yield % of 4.27 is 567.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Santen Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median FCF Yield % is 0.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Santen Pharmaceutical Co's current FCF Yield % is 4.27, which is 17% above median its own 10-year median of 3.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Santen Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Santen Pharmaceutical Co (SNPHY) is currently considered Modestly Overvalued. The stock's GF Value™ is $10.08, compared to a current price of $12.76 — trading 26.6% above its estimated fair value. The current FCF Yield % is 4.27, which is 17% above median its 10-year median of 3.65 and 567.2% above the Drug Manufacturers industry median of 0.64. Santen Pharmaceutical Co's overall GF Score™ is 82/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Santen Pharmaceutical Co (SNPHY), the current FCF Yield % is 4.27 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Santen Pharmaceutical Co (SNPHY) Overvalued in 2026?
Based on GuruFocus' analysis, Santen Pharmaceutical Co stock appears to be overvalued.
The current stock price of $12.76 is trading 26.6% above its estimated GF Value™ of $10.08.
GuruFocus considers Santen Pharmaceutical Co to be Modestly Overvalued.
Key valuation signals for SNPHY:
FCF Yield %: 4.27 (17% above median its 10-year median of 3.65)
GF Value™: $10.08 vs. price of $12.76 (26.6% above fair value)
Industry Position: 567.2% above the Drug Manufacturers median (#298 of 1001)
No single metric tells the full story. See the SNPHY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Santen Pharmaceutical Co Ltd is a drug manufacturing company that focuses on ophthalmic products. The company provides a wide range of prescription and over-the-counter eye care products, including treatments for glaucoma, dry eye, and allergies. It also develops surgical and diagnostic devices related to eye care.
82GF Score
Get the complete analysis for SNPHY
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SNPHY has been successfully added to your 
